I am a medical oncologist who specializes in the care of patients with lung cancers, particularly non small-cell lung cancers. I am dedicated to identifying better treatments for people with all stages of disease and to providing compassionate care for patients and their families. My research focuses on developing innovative and effective ways to harness the body’s immune system to fight cancer. I am a member of the Immunotherapeutics Group, where we design and lead early-phase clinical trials of immunotherapies for patients with a variety of different cancers.
- Clinical Expertise: Lung cancer; Immunotherapy; Clinical trials
- Languages Spoken: English
- Education: MD, Johns Hopkins University School of Medicine
- Residencies: Massachusetts General Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Matthew D. Hellmann
- A Phase I Study Assessing the Immunomodulatory Activity of LY2157299 in Patients with Advanced Solid Tumors
- A Phase I Study of MPDL3280A (Anti-PD-L1) plus INCB024360 in Patients with Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer
- A Phase I Study of Nivolumab with Combination Chemotherapy for Patients with Previously Untreated Stage IIIB or IV Non-Small Cell Lung Cancer
- A Phase IB Study of MPDL3280A plus Cobimetinib in Patients with Locally Advanced or Metastatic Solid Tumors